Time Course for Omalizumab Examined in Early, Late Allergic Reaction
HealthDay News — For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.
Jordis Trischler, MD, from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week 1, 2, 4, and 4, bronchial allergen provocations were repeated.
The researchers observed a significant reduction in EAR after 4 weeks (change in forced expiratory volume in 1 second [ΔFEV1], 28 versus 11%; P<0.001; exhaled nitric oxide, 86 versus 53 ppb; P<0.05), and there was a reduction in basophil activation after two weeks (CD63 expression, 79 versus 32%; P<0.05). After one week there was a reduction in LAR (ΔFEV1, 26 versus 13%; P<0.05).
"These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy," the authors write.